281 related articles for article (PubMed ID: 25755489)
1. Current status of immunosuppression in liver transplantation.
Choudhary NS; Saigal S; Shukla R; Kotecha H; Saraf N; Soin AS
J Clin Exp Hepatol; 2013 Jun; 3(2):150-8. PubMed ID: 25755489
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive Drugs in Liver Transplant: An Insight.
Panackel C; Mathew JF; Fawas N M; Jacob M
J Clin Exp Hepatol; 2022; 12(6):1557-1571. PubMed ID: 36340316
[TBL] [Abstract][Full Text] [Related]
3. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
5. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
7. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
8. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
9. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
10. Basics and Art of Immunosuppression in Liver Transplantation.
Poudel S; Gupta S; Saigal S
J Clin Exp Hepatol; 2024; 14(3):101345. PubMed ID: 38450290
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
12. Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction.
LaMattina JC; Jason MP; Hanish SI; Ottmann SE; Klassen DK; Potosky D; Hutson WR; Barth RN
Transplantation; 2014 Jan; 97(2):133-7. PubMed ID: 24342980
[TBL] [Abstract][Full Text] [Related]
13. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
15. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation.
De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Filipponi F
Best Pract Res Clin Gastroenterol; 2017 Apr; 31(2):199-209. PubMed ID: 28624108
[TBL] [Abstract][Full Text] [Related]
16. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
[TBL] [Abstract][Full Text] [Related]
17. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
18. Egyptian clinical practice guideline for kidney transplantation.
Shokeir AA; Hassan S; Shehab T; Ismail W; Saad IR; Badawy AA; Sameh W; Hammouda HM; Elbaz AG; Ali AA; Barsoum R
Arab J Urol; 2021 Jan; 19(2):105-122. PubMed ID: 34104484
[No Abstract] [Full Text] [Related]
19. Calcineurin-inhibitor-sparing immunosuppressive protocols.
Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
[TBL] [Abstract][Full Text] [Related]
20. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
